Published in Am J Physiol Renal Physiol on August 27, 2014
Pharmacological inhibition of soluble epoxide hydrolase prevents renal interstitial fibrogenesis in obstructive nephropathy. Am J Physiol Renal Physiol (2014) 0.91
Soluble epoxide hydrolase inhibitor 1-trifluoromethoxyphenyl-3- (1-propionylpiperidin-4-yl) urea attenuates bleomycin-induced pulmonary fibrosis in mice. Cell Tissue Res (2015) 0.88
Epoxyeicosatrienoic acids, hypertension, and kidney injury. Hypertension (2015) 0.87
The 2014 Bernard B. Brodie award lecture-epoxide hydrolases: drug metabolism to therapeutics for chronic pain. Drug Metab Dispos (2015) 0.81
MicroRNA-27a promotes renal tubulointerstitial fibrosis via suppressing PPARγ pathway in diabetic nephropathy. Oncotarget (2016) 0.79
Genetic deletion of soluble epoxide hydrolase attenuates inflammation and fibrosis in experimental obstructive nephropathy. Mediators Inflamm (2015) 0.77
Role of phosphatase activity of soluble epoxide hydrolase in regulating simvastatin-activated endothelial nitric oxide synthase. Sci Rep (2015) 0.77
Renal Ischemia/Reperfusion Injury in Soluble Epoxide Hydrolase-Deficient Mice. PLoS One (2016) 0.76
Post-Natal Inhibition of NF-κB Activation Prevents Renal Damage Caused by Prenatal LPS Exposure. PLoS One (2016) 0.75
A dual COX-2/sEH inhibitor improves the metabolic profile and reduces kidney injury in Zucker diabetic fatty rat. Prostaglandins Other Lipid Mediat (2016) 0.75
Podocyte-specific soluble epoxide hydrolase deficiency in mice attenuates acute kidney injury. FEBS J (2017) 0.75
Epoxyeicosatrienoic Acid Analog Decreases Renal Fibrosis by Reducing Epithelial-to-Mesenchymal Transition. Front Pharmacol (2017) 0.75
Suppression of experimental glomerulonephritis by antiserum against transforming growth factor beta 1. Nature (1990) 4.64
Origin and function of myofibroblasts in kidney fibrosis. Nat Med (2013) 4.55
Soluble epoxide hydrolase is a therapeutic target for acute inflammation. Proc Natl Acad Sci U S A (2005) 4.07
Soluble epoxide hydrolase regulates hydrolysis of vasoactive epoxyeicosatrienoic acids. Circ Res (2000) 3.70
Soluble epoxide hydrolase as a therapeutic target for cardiovascular diseases. Nat Rev Drug Discov (2009) 3.46
Acute kidney injury: a springboard for progression in chronic kidney disease. Am J Physiol Renal Physiol (2010) 3.25
Peroxisome proliferation-associated control of reactive oxygen species sets melanocortin tone and feeding in diet-induced obesity. Nat Med (2011) 3.09
TGF-beta in renal injury and disease. Semin Nephrol (2007) 2.65
Angiotensin II activates the Smad pathway in vascular smooth muscle cells by a transforming growth factor-beta-independent mechanism. Circulation (2005) 2.55
Renal fibrosis: novel insights into mechanisms and therapeutic targets. Nat Rev Nephrol (2010) 2.55
NF-kappa B and Sp1 regulate transcription of the human monocyte chemoattractant protein-1 gene. J Immunol (1994) 2.40
TGF-β1-containing exosomes from injured epithelial cells activate fibroblasts to initiate tissue regenerative responses and fibrosis. J Am Soc Nephrol (2012) 2.24
Quantitative profiling method for oxylipin metabolome by liquid chromatography electrospray ionization tandem mass spectrometry. Anal Chem (2009) 2.16
Epoxide hydrolase and epoxygenase metabolites as therapeutic targets for renal diseases. Am J Physiol Renal Physiol (2005) 2.10
The antiinflammatory effect of laminar flow: the role of PPARgamma, epoxyeicosatrienoic acids, and soluble epoxide hydrolase. Proc Natl Acad Sci U S A (2005) 2.10
Prevention and reversal of cardiac hypertrophy by soluble epoxide hydrolase inhibitors. Proc Natl Acad Sci U S A (2006) 2.07
A role of poly (ADP-ribose) polymerase in NF-kappaB transcriptional activation. Biol Chem (1999) 2.06
Soluble epoxide hydrolase is a main effector of angiotensin II-induced hypertension. Hypertension (2005) 2.01
Genomic cloning and promoter analysis of macrophage inflammatory protein (MIP)-2, MIP-1 alpha, and MIP-1 beta, members of the chemokine superfamily of proinflammatory cytokines. J Immunol (1993) 1.99
The enzymatic and DNA binding activity of PARP-1 are not required for NF-kappa B coactivator function. J Biol Chem (2001) 1.88
PPAR-gamma agonist attenuates renal interstitial fibrosis and inflammation through reduction of TGF-beta. Lab Invest (2008) 1.68
Soluble epoxide hydrolase gene deletion attenuates renal injury and inflammation with DOCA-salt hypertension. Am J Physiol Renal Physiol (2009) 1.64
An epoxide hydrolase inhibitor, 12-(3-adamantan-1-yl-ureido)dodecanoic acid (AUDA), reduces ischemic cerebral infarct size in stroke-prone spontaneously hypertensive rats. J Cardiovasc Pharmacol (2005) 1.59
Cellular mechanisms of tissue fibrosis. 3. Novel mechanisms of kidney fibrosis. Am J Physiol Cell Physiol (2013) 1.57
Actions of epoxygenase metabolites on the preglomerular vasculature. J Am Soc Nephrol (1996) 1.50
Reactive oxygen species/oxidative stress contributes to progression of kidney fibrosis following transient ischemic injury in mice. Am J Physiol Renal Physiol (2009) 1.50
Renal ischemia reperfusion inhibits VEGF expression and induces ADAMTS-1, a novel VEGF inhibitor. Am J Physiol Renal Physiol (2008) 1.46
Prevention of hypertension in DOCA-salt rats by an inhibitor of soluble epoxide hydrolase. Cell Biochem Biophys (2007) 1.38
Cytochrome p450 epoxygenase metabolism of arachidonic acid inhibits apoptosis. Mol Cell Biol (2001) 1.34
Two structurally distinct kappa B sequence motifs cooperatively control LPS-induced KC gene transcription in mouse macrophages. J Immunol (1995) 1.29
Soluble epoxide inhibition is protective against cerebral ischemia via vascular and neural protection. Am J Pathol (2009) 1.23
Peroxisome proliferator-activated receptor-gamma abrogates Smad-dependent collagen stimulation by targeting the p300 transcriptional coactivator. FASEB J (2009) 1.22
Pioglitazone prevents early-phase hepatic fibrogenesis caused by carbon tetrachloride. Biochem Biophys Res Commun (2002) 1.21
Inhibition of the soluble epoxide hydrolase promotes albuminuria in mice with progressive renal disease. PLoS One (2010) 1.11
Deletion of soluble epoxide hydrolase gene improves renal endothelial function and reduces renal inflammation and injury in streptozotocin-induced type 1 diabetes. Am J Physiol Regul Integr Comp Physiol (2011) 1.11
Cell death and fibrogenesis. Semin Liver Dis (2010) 1.09
National Kidney Foundation consensus conference on cardiovascular and kidney diseases and diabetes risk: an integrated therapeutic approach to reduce events. Kidney Int (2010) 1.04
Unique mechanistic insights into the beneficial effects of soluble epoxide hydrolase inhibitors in the prevention of cardiac fibrosis. Proc Natl Acad Sci U S A (2013) 1.03
Poly(ADP-ribose) polymerase 1 activation is required for cisplatin nephrotoxicity. Kidney Int (2012) 1.01
Troglitazone halts diabetic glomerulosclerosis by blockade of mesangial expansion. Kidney Int (2000) 1.00
Fibroblast expression of an IκB dominant-negative transgene attenuates renal fibrosis. J Am Soc Nephrol (2010) 0.97
Heterogeneity of antigen expression explains controversy over glomerular macrophage accumulation in mouse glomerulonephritis. Nephrol Dial Transplant (2003) 0.96
Renal nerves drive interstitial fibrogenesis in obstructive nephropathy. J Am Soc Nephrol (2012) 0.96
Opposite effects of gene deficiency and pharmacological inhibition of soluble epoxide hydrolase on cardiac fibrosis. PLoS One (2014) 0.95
Loss of poly(ADP-ribose) polymerase 1 attenuates renal fibrosis and inflammation during unilateral ureteral obstruction. Am J Physiol Renal Physiol (2011) 0.92
PPARgamma agonist and angiotensin II receptor antagonist ameliorate renal tubulointerstitial fibrosis. J Korean Med Sci (2009) 0.88
Anti-inflammatory mechanism of PPARγ on LPS-induced pulp cells: role of the ROS removal activity. Arch Oral Biol (2011) 0.87
Pharmacological inhibition of soluble epoxide hydrolase prevents renal interstitial fibrogenesis in obstructive nephropathy. Am J Physiol Renal Physiol (2014) 0.91